Literature DB >> 29947322

Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: a randomised controlled clinical trial.

Christina N Katsagoni1, George V Papatheodoridis2, Panagiota Ioannidou2, Melanie Deutsch3, Alexandra Alexopoulou3, Nikolaos Papadopoulos3, Maria-Vasiliki Papageorgiou2, Elizabeth Fragopoulou1, Meropi D Kontogianni1.   

Abstract

Lifestyle interventions remain the cornerstone therapy for non-alcoholic fatty liver disease (NAFLD). This randomised controlled single-blind clinical trial investigated the effect of Mediterranean diet (MD) or Mediterranean lifestyle, along with weight loss, in NAFLD patients. In all, sixty-three overweight/obese patients (50 (sd 11) years, BMI=31·8 (sd 4·5) kg/m2, 68 % men) with ultrasonography-proven NAFLD (and elevated alanine aminotransferase (ALT) and/or γ-glutamyl transpeptidase (GGT) levels) were randomised to the following groups: (A) control group (CG), (B) Mediterranean diet group (MDG) or (C) Mediterranean lifestyle group (MLG). Participants of MDG and MLG attended seven 60-min group sessions for 6 months, aiming at weight loss and increasing adherence to MD. In the MLG, additional guidance for increasing physical activity and improving sleep habits were given. Patients in CG received only written information for a healthy lifestyle. At the end of 6 months, 88·8 % of participants completed the study. On the basis of intention-to-treat analysis, both MDG and MLG showed greater weight reduction and higher adherence to MD compared with the CG (all P<0·05) at the end of intervention. In addition, MLG increased vigorous exercise compared with the other two study groups (P<0·001) and mid-day rest/naps compared with CG (P=0·04). MLG showed significant improvements in ALT levels (i.e. ALT<40 U/l (P=0·03) and 50 % reduction of ALT levels (P=0·009)) and liver stiffness (P=0·004) compared with CG after adjusting for % weight loss and baseline values. MDG improved only liver stiffness compared with CG (P<0·001) after adjusting for the aforementioned variables. Small changes towards the Mediterranean lifestyle, along with weight loss, can be a treatment option for patients with NAFLD.

Entities:  

Keywords:  ALT alanine aminotransferase; AST aspartate aminotransferase; CG control group; GGT zzm321990γ-glutamyl transpeptidase; LSM reliable liver stiffness measurements; MD Mediterranean diet; MDG Mediterranean diet group; MET metabolic equivalents; MLG Mediterranean lifestyle group; NAFLD non-alcoholic fatty liver disease; NFS NAFLD fibrosis score; Intervention; Mediterranean diet; Mediterranean lifestyle; Non-alcoholic fatty liver disease; Sleep; Weight loss

Mesh:

Substances:

Year:  2018        PMID: 29947322     DOI: 10.1017/S000711451800137X

Source DB:  PubMed          Journal:  Br J Nutr        ISSN: 0007-1145            Impact factor:   3.718


  31 in total

1.  Impact of exercise training on the sarcopenia criteria in non-alcoholic fatty liver disease: a systematic review and meta-analysis.

Authors:  Andrea Gonzalez; Mayalen Valero-Breton; Camila Huerta-Salgado; Oscar Achiardi; Felipe Simon; Claudio Cabello-Verrugio
Journal:  Eur J Transl Myol       Date:  2021-03-26

2.  Nonalcoholic Fatty Liver Disease in Children.

Authors:  Katherine F Sweeny; Christine K Lee
Journal:  Gastroenterol Hepatol (N Y)       Date:  2021-12

Review 3.  Diagnostic and Therapy of Nonalcoholic Fatty Liver Disease: A Narrative Review.

Authors:  Elke Roeb
Journal:  Visc Med       Date:  2021-10-26

Review 4.  Circadian Rhythms in the Pathogenesis and Treatment of Fatty Liver Disease.

Authors:  Anand R Saran; Shravan Dave; Amir Zarrinpar
Journal:  Gastroenterology       Date:  2020-02-13       Impact factor: 22.682

Review 5.  Mediterranean diet for patients with non-alcoholic fatty liver disease, a systematic review and meta-analysis of observational and clinical investigations.

Authors:  Masoumeh Akhlaghi; Maryam Ghasemi-Nasab; Maryamsadat Riasatian
Journal:  J Diabetes Metab Disord       Date:  2020-02-17

6.  Exercise as Medicine: The Impact of Exercise Training on Nonalcoholic Fatty Liver Disease.

Authors:  Audrey Thorp; Jonathan G Stine
Journal:  Curr Hepatol Rep       Date:  2020-09-09

Review 7.  Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development.

Authors:  Pau Vancells Lujan; Esther Viñas Esmel; Emilio Sacanella Meseguer
Journal:  Nutrients       Date:  2021-04-24       Impact factor: 5.717

8.  Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4.

Authors:  Khaoula Errafii; Neyla S Al-Akl; Olfa Khalifa; Abdelilah Arredouani
Journal:  J Transl Med       Date:  2021-06-02       Impact factor: 5.531

Review 9.  Beyond the Paradigm of Weight Loss in Non-Alcoholic Fatty Liver Disease: From Pathophysiology to Novel Dietary Approaches.

Authors:  Angelo Armandi; Jörn M Schattenberg
Journal:  Nutrients       Date:  2021-06-08       Impact factor: 5.717

10.  Lifestyle modifications for nonalcohol-related fatty liver disease: a network meta-analysis.

Authors:  Elena Buzzetti; Audrey Linden; Lawrence Mj Best; Angela M Madden; Danielle Roberts; Thomas J G Chase; Suzanne C Freeman; Nicola J Cooper; Alex J Sutton; Dominic Fritche; Elisabeth Jane Milne; Kathy Wright; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.